Chronic lymphocytic leukaemia trials in Belgium

In Belgium 19 Also abroad 308

19 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 1Taking people
A Phase 1 Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Where
Edegem, Gent, Leuven
People
225 worldwide
Run by
Janssen Cilag International
See details and how to join2026-525234-39-00 · EU 2026-525234-39-00
Phase 3Taking people
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Where
Antwerp, Leuven
Age
18 years and over
People
735 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT05947851 · EU 2022-501560-17-00
Phase 2Taking people
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Where
Anderlecht, Brugge, Gent, La Louvière, Leuven, Ottignies-Louvain-la-Neuve, Roeselare, Sint-Niklaas, Verviers
Age
18 years and over
People
249 worldwide
Run by
Loxo Oncology, Inc.
See details and how to joinNCT06588478 · EU 2024-515689-15-01
Phase 1Enrolling by invitation
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
Where
Gent
Age
18 years and over
People
120 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00
Phase 4Taking people
A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Where
Roeselare
Age
18 years and over
People
150 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07218341
Phase 3Taking people
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Where
Edegem, Leuven, Sint-Lambrechts-Woluwe
Age
18 years and over
People
630 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06943872 · EU 2024-517131-52-00
Phase 3Taking people
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Where
Edegem, Ghent, Liège, Roeselare
Age
18 years and over
People
63 worldwide
Run by
CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00
Phase 3Taking people
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
Where
Leuven, Mechelen
Age
18 years and over
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06136559 · EU 2022-501697-19-01
Phase 1/2Taking people
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Where
Ghent
Age
1 year to 17 years
People
70 worldwide
Run by
Incyte Biosciences International Sàrl
See details and how to joinNCT03934372 · EU 2023-509699-41-00
Phase 1/2Taking people
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
Where
Antwerp, Roeselare
Age
18 years and over
People
112 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT05791409 · EU 2022-500305-40-00
Phase 3Taking people
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)
Where
Antwerp, Brugge, Leuven, Roeselare, Sint-Lambrechts-Woluwe
Age
18 years and over
People
746 worldwide
Run by
University Of Cologne
See details and how to join2023-510294-34-00 · EU 2023-510294-34-00
Phase 3Taking people
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Where
Anderlecht, Gent, Kortrijk, Liège, Mechelen, Yvoir
Age
18 years and over
People
500 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06973187 · EU 2025-522860-34-00
Phase 2Taking people
REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)
Where
Leuven, Sint-Lambrechts-Woluwe
Age
18 years and over
People
60 worldwide
Run by
Stichting Hemato-Oncologie voor Volwassenen Nederland
See details and how to joinNCT04523428 · EU 2023-505449-18-00
Phase 3Taking people
A long-term follow-up study for patients treated with Galapagos CAR T cell therapies
Where
Edegem, Leuven, Liège, Roeselare, Sint-Lambrechts-Woluwe
Age
18 years and over
People
309 worldwide
Run by
Lakefront Biotherapeutics
See details and how to join2023-510173-34-00 · EU 2023-510173-34-00
Phase 3Taking people
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Where
Leuven, Sint-Niklaas
Age
18 years and over
People
737 worldwide
Run by
Loxo Oncology, Inc.
See details and how to joinNCT05254743 · EU 2023-507699-38-00
Phase 2Not yet taking people in Belgium
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations
Where
Anderlecht, Gent, La Louvière, Leuven, Yvoir
Age
18 years to 79 years
People
44 worldwide
Run by
The Lymphoma Academic Research Organisation
See details and how to joinNCT07738887 · EU 2025-520893-20-00
Phase 3Taking people
Global Trial in APG2575 for Patients With CLL/SLL
Where
Edegem, Gent, La Louvière, Leuven, Ottignies-Louvain-la-Neuve, Roeselare, Yvoir
Age
18 years to 99 years
People
400 worldwide
Run by
Ascentage Pharma Group Inc.
See details and how to joinNCT06104566 · EU 2023-508005-24-00
Phase 2Taking people
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
Where
Anderlecht, Antwerp, Brugge, Gent, Jette, Leuven, Roeselare, Sint-Lambrechts-Woluwe, Yvoir
Age
18 years to 75 years
People
114
Run by
University of Liege
See details and how to joinNCT03852407 · EU 2024-518568-11-00
Phase 1/2Taking people
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
Where
Edegem, Hasselt, Leuven
Age
18 years and over
People
84 worldwide
Run by
Kartos Therapeutics, Inc.
See details and how to joinNCT04502394